# **Olmesartan Formulation**



Version Revision Date: SDS Number: Date of last issue: 13.09.2019 2.3 10.10.2020 717990-00011 Date of first issue: 01.06.2016

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Olmesartan Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Pharmaceutical

stance/Mixture

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person responsible for the SDS

: EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

#### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1A H360D: May damage the unborn child.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

Signal word : Danger

Hazard statements : H360D May damage the unborn child.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:



# **Olmesartan Formulation**



Version Revision Date: SDS Number: Date of last issue: 13.09.2019
2.3 10.10.2020 717990-00011 Date of first issue: 01.06.2016

P405 Store locked up.

Hazardous components which must be listed on the label:

Olmesartan

#### 2.3 Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

### **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

### Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Olmesartan	144689-63-4	Acute Tox. 4; H302	>= 1 - < 10
		Eye Irrit. 2; H319	
		Repr. 1A; H360D	

For explanation of abbreviations see section 16.

#### **SECTION 4: First aid measures**

# 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

# **Olmesartan Formulation**



Version Revision Date: SDS Number: Date of last issue: 13.09.2019 2.3 10.10.2020 717990-00011 Date of first issue: 01.06.2016

4.2 Most important symptoms and effects, both acute and delayed

Risks : May damage the unborn child.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

**SECTION 5: Firefighting measures** 

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

**SECTION 6: Accidental release measures** 

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

# **Olmesartan Formulation**



Version Revision Date: SDS Number: Date of last issue: 13.09.2019 2.3 10.10.2020 717990-00011 Date of first issue: 01.06.2016

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust.
Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of

# **Olmesartan Formulation**



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 2.3
 10.10.2020
 717990-00011
 Date of first issue: 01.06.2016

engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis	
Cellulose	9004-34-6	TWA OEL-RL	5 mg/m3	ZA OEL	
		(Respirable dust)			
	Further information: Recommended Limit				
		TWA OEL-RL	10 mg/m3	ZA OEL	
		(inhalable dust)	_		
	Further information: Recommended Limit				
		STEL OEL-RL	20 mg/m3	ZA OEL	
		(Dust)	_		
	Further information: Recommended Limit				
Olmesartan	144689-63-	TWA	30 µg/m3 (OEB 3)	Internal	
	4		,		
		Wipe limit	300 μg/100 cm <sup>2</sup>	Internal	

### 8.2 Exposure controls

### **Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

### Personal protective equipment

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,





Version Revision Date: SDS Number: Date of last issue: 13.09.2019
2.3 10.10.2020 717990-00011 Date of first issue: 01.06.2016

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, aprop. gauntlets, disposable

being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Particulates type (P)

### **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

Appearance : powder

Colour : No data available
Odour : No data available
Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

# **Olmesartan Formulation**



Version Revision Date: SDS Number: Date of last issue: 13.09.2019 2.3 10.10.2020 717990-00011 Date of first issue: 01.06.2016

Solubility(ies)

Water solubility : No data available Partition coefficient: n- : No data available

octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available

Molecular weight : No data available

Particle size : No data available

### **SECTION 10: Stability and reactivity**

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

### **SECTION 11: Toxicological information**

### 11.1 Information on toxicological effects

Information on likely routes of : Inhalation exposure Skin contact



# **Olmesartan Formulation**



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 2.3
 10.10.2020
 717990-00011
 Date of first issue: 01.06.2016

Ingestion Eye contact

**Acute toxicity** 

Not classified based on available information.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

**Components:** 

Olmesartan:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg

LD50 (Mouse): > 2.000 mg/kg

LD50 (Dog): > 1.500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Skin corrosion/irritation

Not classified based on available information.

**Components:** 

Olmesartan:

Remarks : No data available

Serious eye damage/eye irritation

Not classified based on available information.

**Components:** 

Olmesartan:

Species : Rabbit Method : Draize Test

Result : Moderate eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

**Components:** 

Olmesartan:

Exposure routes : Skin contact Remarks : No data available

# **Olmesartan Formulation**



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 2.3
 10.10.2020
 717990-00011
 Date of first issue: 01.06.2016

### Germ cell mutagenicity

Not classified based on available information.

### **Components:**

Olmesartan:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Mutagenicity (in vitro mammalian cytogenetic test)

Result: negative

Test Type: Chromosome aberration test in vitro Test system: Chinese hamster lung cells

Result: positive

Test Type: Mouse Lymphoma

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow Application Route: Oral

Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

# Carcinogenicity

Not classified based on available information.

#### Components:

#### Olmesartan:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species: MouseApplication Route: OralExposure time: 6 MonthsResult: negative

### Reproductive toxicity

May damage the unborn child.

### **Components:**

#### Olmesartan:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral



### **Olmesartan Formulation**



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 2.3
 10.10.2020
 717990-00011
 Date of first issue: 01.06.2016

Fertility: NOAEL: 1.000 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Development

Species: Rat

Application Route: Oral

Dose: 1000 milligram per kilogram Result: No teratogenic effects

Test Type: Development

Species: Rabbit Application Route: Oral Dose: 1 milligram per kilogram Result: No teratogenic effects

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: >= 1,6 mg/kg body weight Symptoms: Malformations were observed., Reduced body

weight

Result: Effects on postnatal development

Reproductive toxicity - As-

sessment

Positive evidence of adverse effects on development from

human epidemiological studies.

## STOT - single exposure

Not classified based on available information.

# STOT - repeated exposure

Not classified based on available information.

### Repeated dose toxicity

### **Components:**

### Olmesartan:

Species : Rat

NOAEL : 2.000 mg/kg

Application Route : Oral Exposure time : 24 Months

Remarks : No significant adverse effects were reported

### **Aspiration toxicity**

Not classified based on available information.

### Experience with human exposure

#### **Components:**

#### Olmesartan:

Eye contact : Symptoms: Eye irritation Ingestion : Symptoms: hypotension

Remarks: May cause harm to the unborn child.

Based on Human Evidence

# **Olmesartan Formulation**



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 2.3
 10.10.2020
 717990-00011
 Date of first issue: 01.06.2016

### **SECTION 12: Ecological information**

#### 12.1 Toxicity

No data available

### 12.2 Persistence and degradability

No data available

#### 12.3 Bioaccumulative potential

No data available

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

Not relevant

#### 12.6 Other adverse effects

No data available

### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

# **SECTION 14: Transport information**

### 14.1 UN number

Not regulated as a dangerous good

### 14.2 UN proper shipping name

Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

Not regulated as a dangerous good

### 14.4 Packing group

Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

#### 14.6 Special precautions for user

Not applicable

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

# **Olmesartan Formulation**



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 2.3
 10.10.2020
 717990-00011
 Date of first issue: 01.06.2016

### **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

#### **Full text of H-Statements**

H302 : Harmful if swallowed.

H319 : Causes serious eye irritation. H360D : May damage the unborn child.

#### Full text of other abbreviations

Acute Tox. : Acute toxicity Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

ZA OEL : South Africa. Hazardous Chemical Substances Regulations,

Occupational Exposure Limits

ZA OEL / TWA OEL-RL : Long term occupational exposure limits - recommended limit ZA OEL / STEL OEL-RL : Short term occupational exposure limits - recommended limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways: ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road: AIIC - Australian Inventory of Industrial Chemicals: ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -

# **Olmesartan Formulation**



 Version
 Revision Date:
 SDS Number:
 Date of last issue: 13.09.2019

 2.3
 10.10.2020
 717990-00011
 Date of first issue: 01.06.2016

International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

Repr. 1A H360D Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN